Evidence map›Paper›PMID 31801070›Full record

ArticleCell reports2019

Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4

Assaf Magen, Jia Nie, Thomas Ciucci, Samira Tamoutounour, Yongmei Zhao, Monika Mehta, Bao Tran, Dorian B McGavern, Sridhar Hannenhalli, Rémy Bosselut

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. CD4Science (New York, N.Y.) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. A review of CD4Veterinary immunology and immunopathology · 2024
    Review
  12. Article
  13. Article
  14. Developing synthetic tools to decipher the tumor-immune interactome.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. Article
  16. Lung tumor-infiltrating TScience immunology · 2023
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Assaf MagenLaboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA; Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD, USA.
Jia NieLaboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Thomas CiucciLaboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Samira TamoutounourMetaorganism Immunology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Yongmei ZhaoAdvanced Biomedical and Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Monika MehtaNCI CCR Sequencing Facility, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Bao TranNCI CCR Sequencing Facility, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Dorian B McGavernViral Immunology and Intravital Imaging Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
Sridhar HannenhalliMetaorganism Immunology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Rémy BosselutLaboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA. Electronic address: remy.bosselut@nih.gov.
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USNational Institute of Allergy and Infectious Diseases · USCenter for Cancer Research · USNational Institute of Neurological Disorders and Stroke · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Most current tumor immunotherapy strategies leverage cytotoxic CD8

Indexed as

AnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorHumansImmunotherapyInterferon Type ILymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLNeoplasmsTh1 CellsTranscriptomeTumor MicroenvironmentVirusesInterferon Type Icancer immunotherapyCD4(+) T cellssingle-cell RNA-seqTumor-infiltrating lymphocytes

Identifiers

PMID31801070
PMCPMC6934378
OpenAlexW2992446582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.